(EMN) Eastman Chemical - Ratings and Ratios
Additives, Solvents, Copolyesters, Cellulosics, Plasticizers
EMN EPS (Earnings per Share)
EMN Revenue
Description: EMN Eastman Chemical November 04, 2025
Eastman Chemical Company (NYSE: EMN) is a diversified specialty materials producer operating in the United States, China, and other international markets. Its portfolio is organized into four primary segments: Additives & Functional Products, Advanced Materials, Chemical Intermediates, and Fibers, each targeting a broad set of end-markets ranging from transportation and construction to personal care and electronics.
The Additives & Functional Products segment supplies amine-derived building blocks, surfactant intermediates, soil-fumigant precursors, organic-acid solutions, specialty coalescents, solvents, paint additives, specialty polymers, and heat-transfer/aviation fluids. This segment benefits from ongoing demand for higher-performance coatings and low-VOC formulations, especially in automotive and consumer-goods applications.
Advanced Materials focuses on copolyesters, cellulosic biopolymers, polyvinyl butyral (PVB) sheets, and polyester films used in transportation, durable goods, electronics, construction, medical/pharma, and consumables. The Chemical Intermediates segment delivers olefin and acetyl derivatives, ethylene, commodity solvents, and both non-phthalate and phthalate plasticizers, serving industrial chemicals, construction, health-wellness, and food/feed markets. The Fibers segment produces cellulose-acetate tow, triacetin, acetate flake, acetic acid, and acetic anhydride for filtration media, acetate yarns, staple fibers, wet-laid nonwovens, engineered papers, and specialty fibers for transportation, aerospace, and agricultural uses.
Key financial metrics from FY 2023 show revenue of approximately $11.5 billion, adjusted EBITDA margin near 12 %, free cash flow of $1.2 billion, and a capital-expenditure program of roughly $900 million aimed at expanding sustainable polymer capacity. The segment’s growth is closely tied to macro-level drivers such as the global chemicals market’s 3 % CAGR, tightening regulations on phthalate plastics, and accelerating demand for bio-based and high-performance materials.
For a deeper, data-driven view of Eastman’s valuation dynamics and how its segment trends compare to peers, you may find it worthwhile to explore the detailed analysis available on ValueRay.
EMN Stock Overview
| Market Cap in USD | 6,835m |
| Sub-Industry | Diversified Chemicals |
| IPO / Inception | 1993-10-10 |
EMN Stock Ratings
| Growth Rating | -53.9% |
| Fundamental | 58.2% |
| Dividend Rating | 67.4% |
| Return 12m vs S&P 500 | -47.0% |
| Analyst Rating | 4.15 of 5 |
EMN Dividends
| Dividend Yield 12m | 5.43% |
| Yield on Cost 5y | 4.35% |
| Annual Growth 5y | 5.12% |
| Payout Consistency | 98.3% |
| Payout Ratio | 61.7% |
EMN Growth Ratios
| Growth Correlation 3m | -65.8% |
| Growth Correlation 12m | -91.5% |
| Growth Correlation 5y | -36.7% |
| CAGR 5y | -4.80% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.10 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.36 |
| Sharpe Ratio 12m | -1.13 |
| Alpha | -61.89 |
| Beta | 1.298 |
| Volatility | 37.48% |
| Current Volume | 2783.6k |
| Average Volume 20d | 1521k |
| Stop Loss | 59.1 (-3.3%) |
| Signal | 0.93 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (832.0m TTM) > 0 and > 6% of Revenue (6% = 557.0m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -1.31pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 17.60% (prev 12.05%; Δ 5.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.00b > Net Income 832.0m (YES >=105%, WARN >=100%) |
| Net Debt (4.70b) to EBITDA (1.72b) ratio: 2.73 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (116.2m) change vs 12m ago -2.02% (target <= -2.0% for YES) |
| Gross Margin 24.31% (prev 22.75%; Δ 1.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 61.55% (prev 61.14%; Δ 0.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.56 (EBITDA TTM 1.72b / Interest Expense TTM 218.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.52
| (A) 0.11 = (Total Current Assets 4.02b - Total Current Liabilities 2.39b) / Total Assets 15.22b |
| (B) 0.67 = Retained Earnings (Balance) 10.14b / Total Assets 15.22b |
| (C) 0.08 = EBIT TTM 1.21b / Avg Total Assets 15.08b |
| (D) 1.05 = Book Value of Equity 9.79b / Total Liabilities 9.31b |
| Total Rating: 4.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.22
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 3.54% = 1.77 |
| 3. FCF Margin 4.41% = 1.10 |
| 4. Debt/Equity 0.88 = 2.13 |
| 5. Debt/Ebitda 2.73 = -1.36 |
| 6. ROIC - WACC (= 2.71)% = 3.39 |
| 7. RoE 14.38% = 1.20 |
| 8. Rev. Trend -49.86% = -3.74 |
| 9. EPS Trend 34.62% = 1.73 |
What is the price of EMN shares?
Over the past week, the price has changed by +0.02%, over one month by -4.13%, over three months by +0.76% and over the past year by -36.93%.
Is Eastman Chemical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EMN is around 54.39 USD . This means that EMN is currently overvalued and has a potential downside of -10.97%.
Is EMN a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EMN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 74.6 | 22.1% |
| Analysts Target Price | 74.6 | 22.1% |
| ValueRay Target Price | 59.6 | -2.5% |
EMN Fundamental Data Overview November 04, 2025
P/E Trailing = 8.3713
P/E Forward = 9.3985
P/S = 0.736
P/B = 1.2668
P/EG = 3.1324
Beta = 1.298
Revenue TTM = 9.28b USD
EBIT TTM = 1.21b USD
EBITDA TTM = 1.72b USD
Long Term Debt = 4.78b USD (from longTermDebt, last quarter)
Short Term Debt = 344.0m USD (from shortTermDebt, last quarter)
Debt = 5.13b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.70b USD (from netDebt column, last quarter)
Enterprise Value = 11.54b USD (6.83b + Debt 5.13b - CCE 423.0m)
Interest Coverage Ratio = 5.56 (Ebit TTM 1.21b / Interest Expense TTM 218.0m)
FCF Yield = 3.54% (FCF TTM 409.0m / Enterprise Value 11.54b)
FCF Margin = 4.41% (FCF TTM 409.0m / Revenue TTM 9.28b)
Net Margin = 8.96% (Net Income TTM 832.0m / Revenue TTM 9.28b)
Gross Margin = 24.31% ((Revenue TTM 9.28b - Cost of Revenue TTM 7.03b) / Revenue TTM)
Gross Margin QoQ = 22.39% (prev 24.63%)
Tobins Q-Ratio = 0.76 (Enterprise Value 11.54b / Total Assets 15.22b)
Interest Expense / Debt = 1.09% (Interest Expense 56.0m / Debt 5.13b)
Taxrate = 17.16% (29.0m / 169.0m)
NOPAT = 1.00b (EBIT 1.21b * (1 - 17.16%))
Current Ratio = 1.68 (Total Current Assets 4.02b / Total Current Liabilities 2.39b)
Debt / Equity = 0.88 (Debt 5.13b / totalStockholderEquity, last quarter 5.83b)
Debt / EBITDA = 2.73 (Net Debt 4.70b / EBITDA 1.72b)
Debt / FCF = 11.50 (Net Debt 4.70b / FCF TTM 409.0m)
Total Stockholder Equity = 5.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.47% (Net Income 832.0m / Total Assets 15.22b)
RoE = 14.38% (Net Income TTM 832.0m / Total Stockholder Equity 5.78b)
RoCE = 11.48% (EBIT 1.21b / Capital Employed (Equity 5.78b + L.T.Debt 4.78b))
RoIC = 9.27% (NOPAT 1.00b / Invested Capital 10.84b)
WACC = 6.56% (E(6.83b)/V(11.96b) * Re(10.80%) + D(5.13b)/V(11.96b) * Rd(1.09%) * (1-Tc(0.17)))
Discount Rate = 10.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.06%
[DCF Debug] Terminal Value 70.76% ; FCFE base≈484.6m ; Y1≈538.1m ; Y5≈703.7m
Fair Price DCF = 68.48 (DCF Value 7.86b / Shares Outstanding 114.8m; 5y FCF grow 12.71% → 3.0% )
EPS Correlation: 34.62 | EPS CAGR: -8.62% | SUE: -1.48 | # QB: 0
Revenue Correlation: -49.86 | Revenue CAGR: -5.68% | SUE: -0.13 | # QB: 0
Additional Sources for EMN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle